Barrett’s esophagus is not cancer. It is a precancerous condition in which the normal lining of the lower esophagus is replaced by a different type of tissue, one that resembles the lining of the intestine. This cell change, called intestinal metaplasia, happens in response to chronic acid reflux damage. While Barrett’s esophagus does raise the risk of developing esophageal adenocarcinoma, the actual progression rate is low, and most people with the condition never develop cancer.
What Happens to the Esophagus
The esophagus is normally lined with flat, layered cells similar to skin cells. In people with long-standing gastroesophageal reflux disease (GERD), stomach acid repeatedly damages this lining. Over time, the body replaces those damaged cells with a columnar type of cell that looks and behaves more like intestinal tissue, complete with mucus-producing goblet cells. This swap is the body’s attempt to protect the esophagus from ongoing acid exposure, but the new tissue carries a small risk of eventually becoming abnormal.
To officially diagnose Barrett’s, a doctor needs to see this abnormal tissue extending at least 1 centimeter above where the esophagus meets the stomach during an endoscopy, and a biopsy must confirm the presence of goblet cells under a microscope. Without that biopsy confirmation, it’s not considered Barrett’s esophagus, even if the tissue looks suspicious on camera.
How Often Barrett’s Becomes Cancer
The annual risk of Barrett’s esophagus progressing to esophageal adenocarcinoma is quite small. For shorter segments of abnormal tissue (under 3 centimeters), the yearly progression rate is about 0.07%. For longer segments, it rises to roughly 0.25% per year. To put that in perspective, out of 1,000 people with long-segment Barrett’s, only about two or three would develop cancer in a given year.
Up to 50% of people who do develop esophageal adenocarcinoma have no prior history of reflux symptoms, which makes the condition tricky. Many people with Barrett’s have abnormal acid exposure in the esophagus despite mild or completely absent heartburn. This “silent” reflux means some people are unaware of both their reflux and the tissue changes it causes until a problem is found incidentally or during screening.
The Stages Between Barrett’s and Cancer
Barrett’s esophagus doesn’t jump straight to cancer. It progresses through identifiable stages of increasingly abnormal cell growth called dysplasia. Understanding where you fall on this spectrum determines both your risk level and what happens next.
No Dysplasia
Most people with Barrett’s fall into this category. The intestinal-type cells are present but show no signs of becoming abnormal. The recommended approach is a surveillance endoscopy every 3 to 5 years to check for changes. No treatment of the Barrett’s tissue itself is typically needed at this stage.
Low-Grade Dysplasia
In low-grade dysplasia, cells begin showing mild abnormalities: slightly altered shapes, increased division, and some architectural changes in how they’re arranged. The cells still maintain their basic organization, though. Depending on how widespread the dysplasia is, your doctor may recommend either closer monitoring or treatment to remove the abnormal tissue. The extent of low-grade dysplasia matters: more widespread changes carry a higher risk of progression.
High-Grade Dysplasia
This is the stage closest to cancer without technically being cancer. Cells lose their normal organization entirely. They divide more aggressively, stack up in disordered patterns, and show significant structural abnormalities. High-grade dysplasia is treated rather than just monitored, because it carries a meaningful risk of progressing to adenocarcinoma or may already contain microscopic cancer cells that biopsies haven’t captured.
How Barrett’s Tissue Is Treated
When dysplasia is found, the standard approach is endoscopic eradication therapy, which destroys the abnormal tissue without surgery. The most common technique uses radiofrequency energy delivered through a catheter during an endoscopy. Heat is applied to the Barrett’s tissue, which is then replaced by normal esophageal lining as it heals.
A large meta-analysis found that radiofrequency ablation completely eliminates the intestinal metaplasia in about 78% of patients and eliminates dysplasia in 91%. After successful treatment, the abnormal tissue comes back in roughly 13% of people, which is why ongoing surveillance remains important even after treatment. During and after treatment, the risk of progressing to cancer drops dramatically: only 0.2% of patients developed cancer during treatment and 0.7% after successful eradication.
For high-grade dysplasia or very early cancers confined to the surface lining, endoscopic removal of the visible abnormal tissue is often performed before ablation of the remaining Barrett’s segment. This combination approach has largely replaced esophageal surgery for early-stage disease, sparing patients a major operation with significant recovery time.
Symptoms to Be Aware Of
Barrett’s esophagus itself doesn’t produce symptoms you can feel. What you notice are the symptoms of the underlying reflux that caused it. Classic GERD symptoms like heartburn and regurgitation are common, but many people with Barrett’s experience less obvious signs: chronic throat clearing, a persistent feeling of something stuck in the throat (globus sensation), hoarseness, post-nasal drip, or a lingering cough. In one study of patients with these throat-related symptoms, 88% reported chronic throat clearing, 82% had post-nasal drip, 78% experienced globus sensation, and 76% had hoarseness.
The challenge is that none of these symptoms reliably signal Barrett’s specifically. They overlap with allergies, sinus problems, and garden-variety reflux. And a substantial number of people with Barrett’s have no noticeable symptoms at all. This is why screening endoscopy is recommended for people with multiple risk factors: long-standing GERD (especially more than 5 years), male sex, age over 50, obesity, smoking, and a family history of Barrett’s or esophageal cancer.
Living With Barrett’s Esophagus
A Barrett’s diagnosis can feel alarming, especially when the word “precancerous” comes up. But the numbers are reassuring for most people. The overwhelming majority of those with non-dysplastic Barrett’s will never develop esophageal cancer. What the diagnosis does require is a commitment to periodic endoscopic surveillance so that any progression is caught early, when it’s most treatable.
Managing the underlying reflux is also a core part of living with Barrett’s. Reducing acid exposure helps protect the esophageal lining from further damage, though it hasn’t been definitively proven to reverse the metaplasia that’s already occurred. Weight management, dietary changes, and acid-suppressing medications all play a role in controlling reflux and keeping the esophagus as healthy as possible going forward.